+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Proton pump inhibitor improves breath marker in moderate asthma with gastroesophageal reflux disease



Proton pump inhibitor improves breath marker in moderate asthma with gastroesophageal reflux disease



Respiration; International Review of Thoracic Diseases 74(5): 558-564



Gastroesophageal reflux disease (GERD) influences the symptoms of asthma with acid and oxidative stress. The purpose of this study was to determine the usefulness of measurement of the acid stress marker pH and the oxidative stress marker 8-isoprostane by exhaled breath condensate in proton pump inhibitor (PPI) therapy effect on moderate asthma patients with GERD. The pH and the concentration of 8-isoprostane were measured in the exhaled breath condensate of patients with moderate asthma (n = 36) and healthy subjects (n = 26). Two months of PPI therapy (lansoprazole at 30 mg/day) were done in the asthma patients with (n = 13) or without (n = 13) GERD according to a questionnaire for the diagnosis of reflux disease, and exhaled markers were measured. The pH was lower (7.3 +/- 0.3) and the 8-isoprostane level was higher (27.7 +/- 2.3) in the asthma patients than in the healthy control subjects (pH 7.5 +/- 0.2 and 8-isoprostane 6.6 +/- 1.2). Two months of PPI therapy improved the pH (from 7.2 +/- 0.1 to 7.3 +/- 0.1) and the 8-isoprostane concentration (from 32.7 +/- 3.4 to 19.2 +/- 3.4) in the asthma patients with GERD, along with improvement of GERD symptoms. However, these markers did not change in the asthma patients without GERD. Measurement of the pH and 8-isoprostane level of exhaled breath condensate may be useful to evaluate the influence of GERD on asthma, as well as to determine the timing of intermittent PPI therapy.

(PDF emailed within 0-6 h: $19.90)

Accession: 055260233

Download citation: RISBibTeXText

PMID: 17389779

DOI: 10.1159/000101437


Related references

A proton-pump inhibitor, rabeprazole, improves ventilatory function in patients with asthma associated with gastroesophageal reflux. Scandinavian Journal of Gastroenterology 38(5): 456-461, 2003

Proton-pump inhibitor therapy for gastroesophageal reflux disease: does it treat the asthma?. Chest 127(4): 1097-1098, 2005

A proton pump inhibitor, lansoprazole, ameliorates asthma symptoms in asthmatic patients with gastroesophageal reflux disease. Tohoku Journal of Experimental Medicine 209(3): 181-189, 2006

The role of proton-pump inhibitor therapy in patients with gastroesophageal reflux disease and difficult-to-control asthma. Expert Opinion on PharmacoTherapy 7(15): 2015-2017, 2006

Comparison of gastroesophageal reflux disease symptoms and proton pump inhibitor response using gastroesophageal reflux disease impact scale questionnaire. Journal of Neurogastroenterology and Motility 19(1): 61-69, 2013

Value of the Gastroesophageal Reflux Disease Questionnaire (GerdQ) in predicting the proton pump inhibitor response in coronary artery disease patients with gastroesophageal reflux-related chest pain. Diseases of the Esophagus 29(4): 367-376, 2017

Therapy of gastroesophageal reflux disease and functional dyspepsia overlaps with symptoms after usual-dose proton pump inhibitor: Acotiamide plus usual-dose proton pump inhibitor versus double-dose proton pump inhibitor. Journal of Gastroenterology and Hepatology 33(3): 623-630, 2017

Persistent reflux symptoms in the proton pump inhibitor era: the changing face of gastroesophageal reflux disease. Gastroenterology 139(1): 7-13.E3, 2010

Role of Acid and weakly acidic reflux in gastroesophageal reflux disease off proton pump inhibitor therapy. Journal of Neurogastroenterology and Motility 18(3): 291-297, 2012

Endoscopic grading of gastroesophageal flap valve helps predict proton pump inhibitor response in patients with gastroesophageal reflux disease. Scandinavian Journal of Gastroenterology 46(7-8): 789-796, 2012

Exhaled breath marker in asthma patients with gastroesophageal reflux disease. Journal of Clinical Biochemistry and Nutrition 41(3): 147-153, 2008

Efficacy of Vonoprazan for Gastroesophageal Reflux Symptoms in Patients with Proton Pump Inhibitor-resistant Non-erosive Reflux Disease. Internal Medicine 57(17): 2443-2450, 2018

Prospective evaluation of duodenogastroesophageal reflux in gastroesophageal reflux disease patients refractory to proton pump inhibitor therapy. Digestion 86(4): 315-322, 2013

Distal esophageal reflux accompanies nocturnal gastric acid breakthrough in patients with gastroesophageal reflux disease on proton pump inhibitor bid. Gastroenterology 114(4 PART 2): A56-A57, April 15, 1998

Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease. Medical Clinics of North America 103(1): 15-27, 2018